These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 28541429)

  • 21. Transition from treprostinil to selexipag in patients with pulmonary arterial hypertension: Case series.
    Fanous SM; Janmohamed M
    Am J Health Syst Pharm; 2018 Dec; 75(23):1877-1881. PubMed ID: 30301721
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treprostinil: new drug. Pulmonary artery hypertension: just another (disappointing) prostacycline analogue.
    Prescrire Int; 2006 Oct; 15(85):177-9. PubMed ID: 17128524
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transitioning from i.v. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension.
    Vachiéry JL; Hill N; Zwicke D; Barst R; Blackburn S; Naeije R
    Chest; 2002 May; 121(5):1561-5. PubMed ID: 12006444
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanism- and experience-based strategies to optimize treatment response to the capsaicin 8% cutaneous patch in patients with localized neuropathic pain.
    Treede RD; Wagner T; Kern KU; Husstedt IW; Arendt G; Birklein F; Cegla T; Freynhagen R; Gockel HH; Heskamp ML; Jager H; Joppich R; Maier C; Leffler A; Nagelein HH; Rolke R; Seddigh S; Sommer C; Stander S; Wasner G; Baron R
    Curr Med Res Opin; 2013 May; 29(5):527-38. PubMed ID: 23444968
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High incidence of bloodstream infection due to gram-negative bacilli in patients with pulmonary hypertension receiving intravenous treprostinil.
    López-Medrano F; Fernández-Ruiz M; Ruiz-Cano MJ; Barrios E; Vicente-Hernández M; Aguado JM; Escribano P
    Arch Bronconeumol; 2012 Dec; 48(12):443-7. PubMed ID: 22858303
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension.
    Sadushi-Koliçi R; Skoro-Sajer N; Zimmer D; Bonderman D; Schemper M; Klepetko W; Glatz J; Jakowitsch J; Lang IM
    J Heart Lung Transplant; 2012 Jul; 31(7):735-43. PubMed ID: 22480725
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
    Keogh AM; Jabbour A; Weintraub R; Brown K; Hayward CS; Macdonald PS
    J Heart Lung Transplant; 2007 Nov; 26(11):1079-83. PubMed ID: 18022071
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treprostinil for pulmonary hypertension.
    Vachiéry JL; Naeije R
    Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):183-91. PubMed ID: 15151467
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension.
    Gomberg-Maitland M; Tapson VF; Benza RL; McLaughlin VV; Krichman A; Widlitz AC; Barst RJ
    Am J Respir Crit Care Med; 2005 Dec; 172(12):1586-9. PubMed ID: 16151039
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Subcutaneous treprostinil in congenital heart disease-related pulmonary arterial hypertension.
    Skoro-Sajer N; Gerges C; Balint OH; Kohalmi D; Kaldararova M; Simkova I; Jakowitsch J; Gabriel H; Baumgartner H; Gerges M; Sadushi-Kolici R; Celermajer DS; Lang IM
    Heart; 2018 Jul; 104(14):1195-1199. PubMed ID: 29436381
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The potential for inhaled treprostinil in the treatment of pulmonary arterial hypertension.
    Gessler T; Seeger W; Schmehl T
    Ther Adv Respir Dis; 2011 Jun; 5(3):195-206. PubMed ID: 21300738
    [TBL] [Abstract][Full Text] [Related]  

  • 32. One-year experience with intravenous treprostinil for pulmonary arterial hypertension.
    Benza RL; Tapson VF; Gomberg-Maitland M; Poms A; Barst RJ; McLaughlin VV
    J Heart Lung Transplant; 2013 Sep; 32(9):889-96. PubMed ID: 23953817
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful management of an acute subdural hematoma in a patient dependent on continuous treprostinil infusion therapy.
    Safain M; Shepard M; Rahal J; Kryzanski J; Hwang S; Roguski M; Riesenburger RI
    J Neurosurg; 2013 Apr; 118(4):753-6. PubMed ID: 23373804
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension.
    Channick RN; Olschewski H; Seeger W; Staub T; Voswinckel R; Rubin LJ
    J Am Coll Cardiol; 2006 Oct; 48(7):1433-7. PubMed ID: 17010807
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial.
    Tapson VF; Gomberg-Maitland M; McLaughlin VV; Benza RL; Widlitz AC; Krichman A; Barst RJ
    Chest; 2006 Mar; 129(3):683-8. PubMed ID: 16537868
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension.
    Benza RL; Seeger W; McLaughlin VV; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubin LJ
    J Heart Lung Transplant; 2011 Dec; 30(12):1327-33. PubMed ID: 22055098
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial.
    Jing ZC; Parikh K; Pulido T; Jerjes-Sanchez C; White RJ; Allen R; Torbicki A; Xu KF; Yehle D; Laliberte K; Arneson C; Rubin LJ
    Circulation; 2013 Feb; 127(5):624-33. PubMed ID: 23307827
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Subcutaneous treprostinil for pulmonary hypertension in chronic lung disease of infancy.
    Ferdman DJ; Rosenzweig EB; Zuckerman WA; Krishnan U
    Pediatrics; 2014 Jul; 134(1):e274-8. PubMed ID: 24982101
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transition from IV to subcutaneous prostacyclin: premature withdrawal?
    Shapiro S; Hill NS
    Chest; 2007 Sep; 132(3):741-3. PubMed ID: 17873184
    [No Abstract]   [Full Text] [Related]  

  • 40. Parenteral and inhaled prostanoid therapy in the treatment of pulmonary arterial hypertension.
    McLaughlin VV; Palevsky HI
    Clin Chest Med; 2013 Dec; 34(4):825-40. PubMed ID: 24267307
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.